PDL BioPharma, Inc. (NASDAQ:PDLI) was down 0% (0) to $3.19 and showed a volume of 1.06 mln shares. It has ranged in price between $3.14-$3.22 after having started the session at $3.18 as compared to the previous trading day’s close of $3.19. The GAP was therefore -0.31%. Over the 52-week time span, the stock notched a high price of $3.22 and its minimum price was $2.25. The firm’s stock has a market capitalization of $456.72 mln.
According to Zacks brokerage recommendations, PDL BioPharma, Inc. (NASDAQ:PDLI)’s Buy count is 0 and Strong Buy is 0 while the number of analysts recommending Sell and Strong Sell are 0 and 1, respectively. Also, the Hold rating count is 0, as of 1/11/2019. The analyst recommendations from a month ago are 0 Buy, 0 Strong Buy, 0 Sell, 0 Hold and 1. Strong Sell. Investors might also notice that two months ago the Buy recommendations (0) were less than Sell recommendations (0). The count of Hold ratings in that period was 0. Chicago-based equity research firm Zacks Investment Research has assigned this stock ABR (Average Brokerage Recommendation) of 3, suggesting the market has given up on the stock.
Now, the FactSet Research estimate calls for earnings of US$0.08. A month ago, analyst EPS consensus estimated earnings of US$0.08 per share. They were forecasting US$0.07 per share three months ago. The consensus earnings estimates for the company have stabilized at US$0.05 per share. A month ago, they told us to expect earnings of US$0.05 per share while three months ago their EPS consensus estimate was US$0.04.
PDL BioPharma, Inc. (NASDAQ:PDLI) soared 10% year-to-date. The shares have accelerated in recent weeks, with their price up about 27.6% in the past three months. PDLI rose 5.63%, climbed 6.69% and advanced 24.61% in the week, one month and six months, respectively. The most recent short interest data show 10.91% of the company’s stock are short sold. It would take about 9.3 days to cover all short positions. In terms of volatility, it has a beta coefficient of 0.45 and technical analysis volatility indicator called Average True Range or ATR around 0.12.
PDL BioPharma, Inc. (PDLI) closed 18.89% above its 200-day moving average and is 11.13% above another chart threshold, its 50-day moving average. The stock stands nearly -0.93% off versus the 52-week high and 41.78% away from the 52-week low. The number of shares currently owned by investors are 143.17 mln.